Translate
Text Highlighter

Bookmark

PDF

Share

Report a problem
AMICUS AI
Citation Codes
Equivalent Citations
citation codes
Docket Number
Attorney(S)
Judges
Are you a practicing lawyer?
Enhance your digital presence and reach by creating a Casemine profile.
Upload pleading to use the new AI search
Cites
Cited by
Citation Codes
Equivalent Citations
citation codes
Docket Number
Attorney(S)
Judges

Ex parte PAR PHARMACEUTICAL, INC. (In re State of Alabama v. Par Pharmaceutical, Inc.). Ex parte Mylan Inc., Mylan Pharmaceuticals Inc., and UDL Laboratories, Inc. (In re State of Alabama

MEMORANDUM AND ORDER

WILLIAM C. GRIESBACH, District Judge.

Plaintiff Gruenberg, who is proceeding pro se, lodged a civil rights complaint under 42 U.S.C. § 1983, alleging that his civil rights were violated when for five days he was held in restraints at Waupun Correctional Institution ("WCI") while correctional officers waited for keys which he had swallowed to pass through his digestive system. Gruenberg claims that the conditions under which he was restrained constitute cruel and unusual punishment in violation of the Eighth Amendment and that since he was placed in restraints without notice and an opportunity to be heard, his right to due process under the Fourteenth Amendment was violated as well. The case is before me on the defendants' motion for summary judgment. For the reasons that follow, the motion will be granted.

I. Background

This case arose out of circumstances following the plaintiff's unusual decision to steal a set of keys from a guard and then swallow them. On April 19, 2006, while serving a sentence at Waupun Correctional Institution, Gruenberg gained control of an officer's key ring while the officer was dispensing medication to him. The keys included a handcuff key, as well as a master key for the padlock to waist restraints, and a key to activate cell doors. The officer observed Gruenberg place the keys into his mouth and swallow them. For obvious reasons, an inmate's capture of keys set off a major security alert within the prison, and the warden and deputy warden were both notified immediately. (DPFOF ¶ 32.) The health unit was also alerted, and Gruenberg was taken to the emergency room at Waupun Memorial Hospital. An x-ray confirmed that the keys were in Gruenberg's abdomen and doctors believed he would pass the keys within five days with the help of a drug Gruenberg agreed to take.

After his examination at the hospital, Gruenberg was returned to prison with the keys still inside him. Upon his return, the defendants strapped him, naked, to a concrete bedpost and gave him a "threadbare" mattress in one of twelve cells on A-Wing of the HSC Building. HSC houses inmates who are pending disciplinary hearings for rule violations, have been found guilty of violations or are in Administrative Confinement. Restraints were placed on his arms, legs and chest. The defendants explain that restraints were necessary in order to prevent Gruenberg from re-obtaining control of the keys after he passed them. In other words, if he were left unrestrained, he could pass the keys and then hide them somewhere in his cell or re-ingest them. See, e.g., Malone v. Oklahoma, 168 P.3d 185, 213 (Okla. Crim. App. 2007) (inmate who secreted handcuff key into jail by swallowing it retrieved it from feces and re-swallowed it). After lying on his back for twelve hours in this position, Gruenberg was then strapped to a restraint chair. He alternated between the chair and the bed for five days. He was naked throughout this period, and he claims he was cold. Gruenberg asserts that the lack of exercise and movement hindered his ability to pass the keys through his system, although the defendants note that he was allowed thirteen exercise breaks in five days. Gruenberg also asserts that the position was painful and that he was denied common hygiene items. In addition, although the defendants assert he was allowed to use the bedpan and urinal whenever he requested, Gruenberg alleges he was forced to lie in his own feces on two occasions and was denied the ability to clean himself. The defendants state that he was allowed to wash or shower three times.

II. Analysis A. Motion to Appoint Counsel

I begin with plaintiff's motion(s) to appoint counsel. Although I have already denied these motions, Gruenberg has repeatedly renewed them and in a previous order I indicated the matter would be revisited if circumstances warranted it. It is thus worth setting forth my reasoning for continuing to deny the motion to counsel.

Courts routinely note that there is no statutory provision for appointment of counsel. The statute says that a judge may "request" that an attorney represent a litigant, 28 U.S.C. § 1915(e)(1), and so "appointment of counsel" is actually a polite way of saying that the district judge calls multiple attorneys in an effort to get one of them to take a case for no pay.

Gruenberg asserts that he has significant mental deficiencies and is not schooled in the law. I may take him at his word for both propositions. On the latter point, however, a lack of legal training is not sufficient to justify appointment of counsel because otherwise every pro se litigant would be entitled to free legal representation. Instead, the question is whether a litigant has an adequate ability to alert the court to the nature of his claim and to marshal and explain the facts underlying that claim. This analysis involves not just an inquiry into the mental state of the litigant but also an assessment of the complexity of the case, its potential merit, and such things as the litigant's difficulty of obtaining evidence from a prison cell. "The inquiries are necessarily intertwined; the difficulty of the case is considered against the plaintiff's litigation capabilities, and those capabilities are examined in light of the challenges specific to the case at hand." Pruitt v. Mote, 503 F.3d 647, 655 (7th Cir. 2007). As the Seventh Circuit has noted, a litigant has a right to access the courts, but not a right to have his claims presented effectively. "The right of access to the courts protects prisoners from `being shut out of court,' it does not exist to `enable the prisoner . . . to litigate effectively once in court.'" Id. at 657 (citations omitted).

Here, I have determined twice already that the facts of this case, while unusual, are not so complicated that a reasonable pro se litigant in prison could not prosecute the action. I reiterate that conclusion here. In addition, it is clear that even if Gruenberg suffers from certain mental conditions that the typical inmate does not experience, these have not impacted his ability to defend against the motion for summary judgment. He has filed numerous declarations providing copious amounts of detailed information about what happened to him, almost on an hourly basis, during the period he complains about. His brief sets forth his complaint about the conditions of his confinement. In this Court's experience, Gruenberg's presentation of the facts was significantly above the average pro se litigant's capabilities. There is no mystery what this case is about; to put it another way, if Gruenberg loses it is not because something was left out of his presentation, it is because the facts do not warrant relief. Accordingly, I conclude that Gruenberg is not entitled to appointed counsel.

B. Eighth Amendment

Summary judgment is proper if there are no genuine issues of material fact and the moving party is entitled to judgment as a matter of law. Fed.R.Civ.P. 56. Most of the material facts here are not in dispute; instead, the parties emphasize different aspects of Plaintiff's treatment in custody and the reasons for that treatment. Where disputes arise, I resolve them at this stage in favor of Gruenberg, the non-moving party.

To succeed on a claim under the Eighth Amendment, Gruenberg needs to present evidence from which a fact finder could conclude that the conditions of his confinement resulted in "the denial of the minimal civilized measure of life's necessities," and that the defendants were deliberately indifferent to the conditions in question, meaning that they knew of and disregarded an excessive risk to Gruenberg's health or safety. See Townsend v. Fuchs, 522 F.3d 765, 773 (7th Cir. 2008) (quoting Farmer v. Brennan, 511 U.S. 825, 834 (1994)). But the Eighth Amendment does not proscribe only those conditions of confinement that are likely to cause death or serious injury. It also proscribes conditions that "involve the wanton and unnecessary infliction of pain," including "pain without any penological purpose." Rhodes v. Chapman, 452 U.S. 337, 347 (1981). Even more fundamentally, the Eighth Amendment protects the basic dignity of the person being punished. See Trop v. Dulles, 356 U.S. 86, 100 (1958) ("The basic concept underlying the Eighth Amendment is nothing less than the dignity of man."); Hope v. Pelzer, 536 U.S. 730, 738 (2002) ("The use of the hitching post under these circumstances violated the `basic concept underlying the Eighth Amendment [, which] is nothing less than the dignity of man.'") (quoting Trop, 356 U.S. at 100.). It prohibits treatment that robs the inmate of his innate dignity as a human being. Bowers v. Pollard, 602 F. Supp. 2d 977 (E.D. Wis. 2009)., aff'd, 2009 WL 2971085 (7th Cir. 2009) (unpublished).

Defendants rely heavily upon this court's decision in Bowers as support for their argument that they are entitled to summary judgment. In that case, the court granted summary judgment despite undisputed evidence that the plaintiff was held naked in essentially the same kind of restraints for as long as twelve hours and was forced to urinate and defecate on himself. But Bowers differs from this case in several significant ways. Not only was Gruenberg restrained for a significantly longer time, but Bowers also had a history of far more extreme and ongoing self-destructive behavior that is not present here. There I noted that "given [Bowers'] repeated efforts to harm himself, even as he was being returned to his cell following a trip to the hospital . . ., it was reasonable to believe he would return to such behavior if not restrained." 602 F. Supp.2d at 990. Here, by contrast, other than the impulsive act of swallowing the keys (and even that's equivocal), the defendants have offered no evidence that Gruenberg was attempting to harm himself or others.

Moreover, even though summary judgment was granted in Bowers, this court noted that the "most troubling" aspect of Bowers' treatment was the fact that he was naked throughout the period of his restraint and was not even released when he needed to use a toilet. Indeed, the court declined to hold that these conditions did not amount to cruel and unusual punishment and instead turned to the question of whether the defendants had acted with the requisite intent:

Forced nudity can degrade and humiliate a prisoner. Refusing to allow him the use of a toilet so that he urinates or defecates on himself adds to the degradation. Absent a justification for such conditions, I am unable to say that they do not fall within the meaning of cruel and unusual punishment proscribed by the Eighth Amendment. . . . . On the record before me, I am unable to determine whether, under the circumstances of this case, these conditions fall below Eighth Amendment standards. I therefore turn to the second element of the claim-whether the defendants denied Bowers civilized conditions of confinement intentionally or recklessly.
Id. at 992. Given the extreme and continuous self-destructive behavior with which the defendants were faced in that case, the court concluded that a reasonable jury could not conclude that the defendants had the requisite intent. Here, it is not so clear.

Defendants contend that it was necessary to place Gruenberg in restraints because of the need to regain control of the keys once they were expelled and keep Gruenberg from passing them to other inmates, hiding them somewhere else, or even re-ingesting them himself. (Doc. 62, ¶¶ 37, 44.) Based on the record before me, a fact finder could conclude otherwise. Gruenberg was released from the restraints and placed in one of the negative airflow cells generally used for inmates suspected of having communicable diseases, such as tuberculosis, on April 24. Located in the HSU, the room had a bed and mattress, and Gruenberg was given clothing, a blanket, soap and a towel. Two days later, on April 26, he was transported to Waupun Memorial Hospital where he underwent endoscopy and colonoscopy to extract the keys. Two of the keys were recovered during the endoscopy, but doctors were unable to remove the third. The following day, Gruenberg was returned to WCI where he was returned to a cell. HSU staff continued to monitor him and check his stools until the third key was passed on May 3, 2006. Based on these facts, Gruenberg reasonably contends that there was never a need for the mechanical restraints, especially after the first twelve hours, and defendants could have placed him in a cell in HSU initially.

But even if Gruenberg did need to be restrained, why was it necessary to keep him completely naked and uncovered throughout the entire period, especially at night when he complained of being cold? And why, if his version is to be taken as true, which it must at this stage of the proceedings, was he left to sit in his own feces and urine? Defendants claim that inmates placed in restraints are strip searched and not allowed to have any clothing to ensure that they don't have access to weapons or contraband. ( Id., ¶¶ 53, 54.) They are not allowed a blanket because the security staff must be able to ensure that the inmate is breathing and that he has not slipped out of the velcro restraints. ( Id., ¶ 123.) These explanations also seem weak. The reason for conducting a strip search is to make sure the inmate has no weapon or other contraband hidden anywhere on, or in, his person. Once the strip search is completed, this risk would seem to be eliminated. And to the extent it is necessary for the restraints to remain uncovered so the guards can be sure the inmate doesn't slip out of them, no reason appears why the inmate could not be at least partially covered.

If, as defendants contend, the temperature in Gruenberg's cell ranged between 72 and 77 degrees, a jury could reject his claim that keeping him naked and immobilized all night on a "threadbare mattress" placed over concrete without a blanket amounts to cruel and unusual punishment. But Gruenberg notes that the temperatures the defendants cite were taken in hallways, and not in the cells whose back walls formed the outer wall of the building, and contends he was extremely cold. See Gillis v. Litscher, 468 F.3d 488 (7th Cir. 2006) (holding that inmate's claim that he was cold when placed in cell with no clothing or bedding, combined with the denial of toilet paper and other personal hygiene articles, sufficient to show Eighth Amendment violation even though the evidence showed that his cell was kept at 70 degrees or above). Finally, it is worth noting that the Wisconsin Department of Corrections regulation that authorizes the use of mechanical restraints to immobilize inmates, Wis. Adm. Code § DOC 306.11, says nothing about removing the inmate's clothing. It does state, however, that "[i]f possible, staff may release an inmate from restraints to perform bodily functions and for meals." § DOC 306.11(3)(c).

Based on the foregoing, I conclude that a reasonable fact finder could conclude from the evidence viewed in the light most favorable to the plaintiff that the conditions to which Gruenberg was subjected over the five-day period while prison staff were waiting for the keys to pass amounted to cruel and unusual punishment. I therefore proceed to the defendants claim that they are entitled to qualified immunity.

C. Qualified Immunity

Even assuming the conditions under which Gruenberg was held amount to cruel and unusual punishment, I conclude that the defendants are entitled to qualified immunity. The doctrine of qualified immunity protects government officials "from liability for civil damages insofar as their conduct does not violate clearly established statutory or constitutional rights of which a reasonable person would have known." Harlow v. Fitzgerald, 457 U.S. 800, 818 (1982). "Qualified immunity balances two important interests-the need to hold public officials accountable when they exercise power irresponsibly and the need to shield officials from harassment, distraction, and liability when they perform their duties reasonably." Pearson v. Callahan, 129 S.Ct. 808, 815 (2009). All officials, save the "plainly incompetent or those who knowingly violate the law" are protected by qualified immunity. Malley v. Briggs, 475 U.S. 335, 341 (1986).

This case presents a classic situation in which the doctrine is required to shield officials acting in good faith in responding to a unique situation that involved both inmate health and prison security. First, the defendants were confronted with what to them was the unprecedented breach of security: Gruenberg had stolen and swallowed a handcuff key, a master key for belt restraints, and one of the keys used for opening cell doors. By doing that, the plaintiff made his own body and its most private and embarrassing functions a matter of prison security. The Eighth Amendment itself, of course, does not provide a clear roadmap as to how prison staff must treat an inmate who has swallowed a set of keys. Thus, the defendants found themselves, to a large extent, in uncharted waters.

The physician who examined Gruenberg informed the prison officials that he would most likely pass the keys within five days. Rather than request immediate surgery, the defendants elected to wait. The defendants also determined, however, in what may have been an abundance of caution that it was necessary that Gruenberg remain without clothing in order to observe and secure the keys once they passed through his system without any chance that he would be able to pass them to another inmate, re-ingest them or secret them on his person. The conditions under which he was placed were thus not based on any wantonness or indifference to his physical or mental health and safety; they were instead the result of what in hindsight appears an overcautious effort to maintain the security of the institution.

In Farmer v. Brennan, the Court held that "a prison official may be held liable under the Eighth Amendment for denying humane conditions of confinement only if he knows that inmates face a substantial risk of serious harm and disregards that risk by failing to take reasonable measures to abate it." 511 U.S. at 847. The record here belies any suggestion that the defendants knew Gruenberg faced any risk of serious harm. Indeed, the defendants took extraordinary steps to insure he did not suffer serious harm. Pursuant to DOC policy, security personnel sought the input of WCI's health and clinical staff throughout the process to insure that Gruenberg's physical and mental health needs were met. Nursing staff from the WCI Health Services Unit ("HSU") were present when Gruenberg was initially placed in restraints to monitor his vital signs and check restraint placement to ensure they did not adversely affect circulation to any part of his body. A clinical staff member of the Psychological Services Unit ("PSU") was also present and evaluated Gruenberg when he was initially placed in restraints. A nurse from HSU checked his condition and documented his or her findings every four hours, and clinical staff saw him regularly as well. Nurses applied antibiotic ointment to scabbed areas and lotion to dry parts of his skin. They also applied a bandage to his tailbone area, which had become reddened and sore. Finally, Gruenberg's condition was also checked by security staff every fifteen minutes throughout the period he was restrained, and a log was kept of his condition and concerns. Although Gruenberg disputes their findings and claims they failed to note all of his complaints, it is undisputed that he was assessed by nurses from the HSU some thirty-one times during the five-day period. He was visited and assessed by the clinical staff from the PSU nine times. Medical and mental health monitoring and treatment on this scale is simply inconsistent with the claim that the defendants intentionally or recklessly acted to subject Gruenberg to cruel and unusual punishment.

More importantly for purposes of determining whether the defendants are entitled to qualified immunity, I note that Plaintiff has sued some twenty-five people, including several nurses, licensed psychologists and other health care providers. This at least weakens the claim that Gruenberg's right to be free of the conditions he complains about was "clearly established." The idea that so many trained prison staff members, including health providers, would have failed to recognize a constitutional violation is difficult to believe. "The relevant, dispositive inquiry in determining whether a right is clearly established is whether it would be clear to a reasonable officer that his conduct was unlawful in the situation he confronted." Saucier v. Katz, 533 U.S. 194, 202 (2001). I do not suggest that the number of defendants is itself dispositive in such an inquiry, but here the record shows that these multiple defendants were working in concert with each other — monitoring Plaintiff's restraints, temperature, psychological status, etc., and treating his scabs and wounds — and that all of them evidently believed their actions were reasonable under the circumstances. This at least suggests that any additional rights Gruenberg may have had were not clearly established.

More importantly, the unusual circumstance Gruenberg created has little precedent that staff members could reasonably have appreciated. Notably, neither side has been able to cite any precedential case even remotely similar to this one, where an inmate's own behavior created a security and health risk that required the ad hoc imposition of unique conditions of confinement for a limited period. This is not to say that officials are off the hook anytime a similar case does not exist, but it is a practical recognition that there was simply no constitutional benchmark here to which prison staff could measure their response. Qualified immunity is designed to shield officials from liability when they exercise their judgment, particularly in gray areas where the contours of the Eighth Amendment are not clear. Here, they exercised their judgment in a case involving both prison security and the inmate's health, and in a case like this the immunity doctrine means they are entitled to the benefit of the doubt. Elliott v. Thomas, 937 F.2d 338, 341 (7th Cir. 1991).

Plaintiff cites Friends v. Moore, 776 F. Supp. 1382 (E. D. Mo. 1991), in which an inmate swallowed a cuff key and was placed in a dry cell and ultimately a "strip cell." In that case, however, the court found no constitutional violation because the defendants' actions were required to restore order.

D. Due Process

Plaintiff's complaint also suggests (albeit in a footnote) that his conditions of confinement violated Due Process. Under Sandin v. Conner, 515 U.S. 472, 484 (1995), prison discipline that involves "atypical and significant hardship in relation to ordinary incidents of prison life" requires the prison to give the inmate notice and an opportunity to be heard, i.e., a chance to explain his conduct before the prison imposes the disciplinary conditions. The problem is that the conditions

imposed here, as explained above, were not disciplinary in nature but were designed to retrieve the keys Gruenberg had swallowed and prevent him from reacquiring them. That is, the determination to place Gruenberg in restraints was not punishment for an infraction, and as such it would not have made sense to hold a hearing or allow Gruenberg to explain himself: the x-rays showed the keys in his system and he never denied ingesting them. As the Seventh Circuit noted in Bowers, such claims "are better conceptualized under the Eighth Amendment." 345 Fed. Appx. at 196. Accordingly, to the extent Gruenberg brings a due process claim, it is dismissed as well.

III. Conclusion

For the reasons given above, the defendants' motion for summary judgment is GRANTED. All other pending motions are DENIED. The case is DISMISSED.

Plaintiff filed several discovery motions, but they are now moot. In granting summary judgment to the defendants, I accepted all of Plaintiff's allegations as true. As such, additional discovery would not have been material to the outcome here.

<>kquote

The parties in the present petitions have attached as exhibits the pending summary-judgment motions and the State's responses, and we express no opinion as to the merits of the matters raised in those materials. We do note, however, that it is clear from those materials as well as the other materials before us that the parties vigorously dispute whether the AstraZeneca decision disposes of the State's claims in the underlying cases.

The State contends, for example, that Par and Mylan are taking inconsistent positions by arguing "on the one hand, that [the cases against them] are separate and distinct cases which cannot be consolidated" but arguing "on the other hand that [the cases] should be considered exactly the same as AstraZeneca and SandozL Inc. v. State (No. 1081402)] for the purposes of claim preclusion." (State's answer, p. 19.) In the trial court, the State cited Mylan's earlier contention that there are "significant, substantive differences between the Medicaid reimbursement of brand and generic pharmaceutical products under the rules of the Alabama Medicaid Program." State's Opposition to Defendants' Motion to Vacate or Stay Order Setting Mylan Defendants for Trial on June 14, 2010. Additionally, the State contended that

"[b]ecause Mylan's drugs are almost entirely generic and not brands, there is no mathematical relationship between the AWP and WAC prices reported by Mylan and used by [Alabama Medicaid] to reimburse pharmacies. Unlike brand drugs where reported AWP prices generally exceed reported WAC prices by either 20% or 25%, there is no such connection between AWP and WAC for generic drugs. That is, there was no rhyme or reason to the percentage markup of AWP over WAC for any particular Mylan drug, and there was certainly no mathematical relationship between Mylan's AWP and WAC prices across the board. Therefore, even assuming that the State knew that Mylan's reported AWP prices were inflated (which the State did not), it would be absolutely impossible for the State to conclude from such knowledge alone that Mylan's WAC prices were also inflated or to estimate the amount of such inflation."
Id.

The State correctly points out that a denial of a motion for a summary judgment is, with limited exceptions not applicable here, not reviewable on a petition for the writ of mandamus. In Ex parte Liberty National Life Insurance Co., 825 So.2d 758 (Ala. 2002), we stated:

"Subject to certain narrow exceptions not applicable here, we have held that, because an `adequate remedy' exists by way of an appeal, the denial of a motion to dismiss or a motion for a summary judgment is not reviewable by petition for writ of mandamus. See Ex parte Jackson, 780 So.2d 681, 684 (Ala. 2000) (quoting Ex parte Empire Fire Marine Ins. Co., 720 So.2d 893, 894 (Ala. 1998), quoting in turn Ex parte Central Bank of the South, 675 So.2d 403 (Ala. 1996), for the general rale that' "`a writ of mandamus will not issue to review the merits of an order denying a motion for a summary judgment,' "` but noting that narrow exceptions exist, such as in cases involving governmental immunity); Ex parte Newco Mfg. Co., 481 So.2d 867, 870 (Ala. 1985) (`In its Mandamus petition as addressed to its motion for summary judgment based on the statute of repose contained in the Tennessee products liability act, Newco seeks "to do by mandamus that which can be done on appeal."` (quoting Ex parte South Carolina Ins. Co., 412 So.2d 269 (Ala. 1982))); see also Ex parte Mobile County Dep't of Human Res., 815 So.2d 527 (Ala. 2001) (issuing writ of mandamus to reverse an order denying a motion to dismiss asserting defense of immunity); Ex parte Alabama Dep't of Forensic Sciences, 709 So.2d 455 (Ala. 1997) (permitting review by petition for a writ of mandamus in case involving immunity). Because the relief Liberty National seeks in its mandamus petition can be adequately attained by an appeal, Liberty National is not entitled to a writ of mandamus to review the denial of its motion."

825 So.2d at 761-62 (emphasis added). See also Ex parte Griffin, 4 So.3d 430, 435 (Ala. 2008) ("Generally, the denial of a motion for a summary judgment is not reviewable by a petition for a writ of mandamus.").

We agree with the State that the instant petitions are analogous to a petition for the writ of mandamus seeking review of the denial of a motion for a summary judgment. If the AstraZeneca decision indeed is dispositive of the State's claims against Par and Mylan — a question as to which we express no opinion here — and the trial court rules erroneously on that issue, Par and Mylan will be able to obtain adequate relief by an appeal. To the extent that Par and Mylan are asking us to create a new exception to the rule that we do not review such questions on a petition for the writ of mandamus, we decline the request. Moreover, the underlying proceedings have not progressed to the procedural stage at which such a review on the merits would be possible, nor is the evidentiary record in the present petitions developed sufficiently for us to review the substantive merits of Par's and Mylan's contentions regarding the applicability of AstraZeneca to the underlying cases.

Thus, Par and Mylan have not demonstrated that they are entitled to the writ of mandamus on the alleged basis that AstraZeneca is dispositive of the State's claims against them. See Ex parte Liberty Nat'l, supra; Ex parte Griffin, supra. See also Novartis II, 991 So.2d at 1280 ("` "This Court does not issue the writ of mandamus based on mere speculation as to the possible occurrence of future events."`" (quoting Ex parte Flexible Prods. Co., 915 So.2d 34, 41 (Ala. 2005), quoting in turn Ex parte Vance, 900 So.2d 394, 398-99 (Ala. 2004))).

II.

Par and Mylan contend that the trial court exceeded its discretion in finding the existence of a common issue of law or fact. In Novartis II, we stated:

"Rule 42(a), Ala. R. Civ. P., provides:
"`When actions involving a common question of law or fact are pending before the court, it may order a joint hearing or trial of any or all the matters in issue in the actions; it may order all the actions consolidated; and it may make such orders concerning proceedings therein as may tend to avoid unnecessary costs or delay.'
"`We have said that "[c]ircuit judges have broad powers under the Alabama Rules of Civil Procedure . . . to order actions consolidated." ` Ex parte Flexible Prods. Co., 915 So.2d at 39 (quoting State v. Reynolds, 887 So.2d 848, 854 (Ala. 2004)). `[Rule 42(a)] specifically recognizes the propriety of consolidation, as well as the trial court's discretion to order consolidation as necessary to reduce costs or delay.' Owens-Corning Fiberglass Corp. v. James, 646 So.2d 669, 674 (Ala. 1994)."

991 So.2d at 1274. We then stated the following regarding the existence of a common question of law or fact:

"Rule 42(a) permits joint trials when the cases share `a common question of law or fact.' Ala. R. Civ. P. 42(a). One of either — law or fact — will suffice as the basis for invoking the rule. See also 33 Fed. Proc, L.Ed. § 77:44 (1995) (`Actions involving the same parties are likely candidates for consolidation, but a common question of law or fact is enough; if a common question exists, courts often consolidate actions despite differences in parties.'); 9A Charles Alan Wright Arthur R. Miller, Federal Practice and Procedure § 2382 (3d ed. 2008) (`The existence of a common question by itself is enough to permit consolidation under Rule 42(a), [Fed.R.Civ.P.,], even if the claims arise out of independent transactions.'). Further, consolidation under Rule 42 does not require that common issues predominate over other issues. See Ex parte Flexible Prods. Co., 915 So.2d at 42 (`Moreover, we reject the argument presented by the defendants that the propriety of the [case-management order] rests upon a determination of whether any common issues "predominate" over the other issues in the actions to be consolidated. A weighing of the relative dominance of the particular issues presented by actions to be consolidated (an exercise that would be speculative in actions such as this where the common issues have yet to be framed) is not required by Rule 42.')."

991 So.2d at 1277.

In its consolidation order, the trial court found the following common issues of fact and law in the actions against Par and Mylan:

"• That each defendant allegedly participates in Alabama's Medicaid program;
"• That each defendant allegedly reported the prices for its drug(s) at issue to First DataBank (`Blue Book') and Medical Economics, Inc. (`Red Book');
"• That each defendant allegedly knew that Alabama Medicaid relied upon and utilized the prices reported by such defendant to Blue Book and Red Book as the basis to reimburse providers making Medicaid claims;
"• That each defendant allegedly gave undisclosed discounts, rebates, and other inducements to medical providers (which had the effect of lowering the actual wholesale or sale price charged to its customers);
"• That each defendant allegedly falsely reported inflated prices to Blue Book and Red Book and allegedly concealed its actual, lower prices;
"• That each defendant allegedly knew that its price reporting would result in Alabama Medicaid paving excessive amounts for reimbursement of those drugs;
"• That Alabama Medicaid allegedly relied upon each defendant to report its prices in a truthful manner to the price reporting services used by Alabama Medicaid to reimburse providers;
"• That each defendant's alleged wrongful reporting of price information resulted in monetary damages to the State."

Par and Mylan focus primarily on Par's contention that it did not routinely report its wholesale acquisition costs ("WACs") to third-party publishers. Par and Mylan point out that in Novartis II both GSK and Novartis admitted that they provided information to third-party publishers. See Novartis II, 991 So.2d at 1276 ("GSK admits that. . . . `from time to time, GSK provided price communications to third party publications which contained "WACs" [wholesale acquisition costs] or similar list prices for wholesalers for certain of its drugs.' . . . Similarly, Novartis admits that. . . . `from time to time during the relevant period, Novartis provided price lists to third party publications which contained, inter alia, "AWPs" [average wholesale prices] and "WACs" [wholesale acquisition costs] for certain of its drugs. . . .'"). If indeed this difference between the reporting practices of Mylan and Par exists, we disagree that it means that the trial court exceeded its discretion in finding a common issue of law or fact under Rule 42(a), Ala. R. Civ. P., at this stage in the proceedings.

Mylan admits that it reported its WACs to third-party publishers.

Par concedes in its petition that it "is aware of isolated occasions on which a Par employee mistakenly provided WACs to, or verified WACs already possessed by, a publisher." (Par's petition, p. 9 n. .?.) However, Par contends that its

"evidence would show that, upon learning of such instances, Par would contact the relevant publisher and ask it to remove the Par WAC from its publication. Moreover, such isolated mistakes were irrelevant to [Alabama Medicaid's] standard, continuously applied reimbursement methodology."

(Par's petition, p. 9 n. 3 (emphasis added).)

In addition to the above-listed common issues of law or fact, the trial court in another part of its order noted:

"Evidence concerning the reimbursement formulas and the State's purported use and/or reliance on defendants' reported prices will not differ among [Mylan and Par] as each defendant either reported, caused to be reported or engaged in conduct with a reckless disregard to the truth of the prices allowed to be published for its drugs to First Data-Bank, which, in turn, transmitted the prices to Alabama Medicaid for its use."

(Emphasis added.) The trial court's order also states that the State plans to present as to all defendants (1) the same expert testimony at trial and (2) the same model and methodology for proving its alleged damage. Further, the trial court's order notes that both Par and Mylan have asserted common affirmative defenses to the State's claims. The trial court also found it particularly significant that both Par and Mylan "manufacture[], distribute[], marked], and/or offer[] for sale almost exclusively generic prescription drugs" (emphasis added). Based on the foregoing, the trial court did not exceed its discretion in finding the existence of a common issue of law or fact under Rule 42(a), Ala. R. Civ. P.

The trial court cited the following affirmative defenses: the statute of limitations, the statute of repose, laches, estoppel, waiver, standing, the failure to satisfy federal regulatory requirements, federal preemption, the political-question doctrine, and the filed-rate doctrine.

Par and Mylan contend alternatively that even if the State's cases against them present a common question of law or fact, consolidation is inappropriate because, they say, the consolidation will prejudice the parties, confuse the jury, and waste judicial resources. In support of their contentions, Par and Mylan make the following contentions:

— "The State's claims against Par and its separate claims against Mylan would take multiple weeks to try, and it is likely that the volume of evidence presented during that time would overwhelm the jury's ability to give full and fair consideration to the evidence presented against and by each defendant." (Par's petition, p. 24.)
— The State's allegations against Par relate to the pricing and marketing of 23 drugs associated with 158 unique "National Drug Code" numbers ("NDCs"). According to Par, each of its drugs "was priced and marketed in light of competitive pressures and other variables in each individual product market." (Par's petition, p. 8.) Thus, the number of distinct NDCs for drugs Par priced and marketed represents roughly 20% of the NDCs involved in the State's claims against Par and Mylan.
— The State's allegations against Mylan relate to 153 separate drugs, associated with 633 distinct NDCs. Thus, the number of distinct NDCs for drugs that Mylan priced and marketed represents about 80% of the NDCs involved in the State's claims against Par and Mylan. Par asserts that "the presentation of the vastly larger body of evidence against or for Mylan would unfairly dominate the jury's time and attention. . . . Par's story would be lost in this deluge of evidence." (Par's petition, p. 26.)
— As noted above, Par contends that its policy and practice was to not submit WAC pricing for its generic drugs to industry publishers. Mylan, however, supplied the WAC prices for its generic drugs to such publishers.
— Par asserts that "at least seven of the generic drugs at issue in this case were independently marketed and sold by both Par and Mylan. These overlapping drugs — each pair of which shares the same generic name — aggravate the likelihood that the jury would become confused and fail to recall the distinctions between the defendants. No such problem was present when this Court upheld [in Novartis II] the consolidation of Novartis and GSK — who had no product overlap." (Par's petition, p. 27; cf. Mylan's petition, p. 19.)

The trial court found that consolidation of the trials against Par and Mylan would be "the most efficient and economical disposition of this action." The trial court rejected as "premature and without merit" Par's and Mylan's claims that they would be prejudiced by the consolidation. The trial court cited its own experience in trying the consolidated cases against GSK and Novartis, and it stated that during that the trial of the GSK and Novartis cases

"the jury repeatedly was made aware, from the outset, that there were two separate cases for its consideration. Special notebooks were prepared, special jury instructions were given, exhibits were separately marked, and numerous other precautionary measures were taken to avoid juror confusion."

The trial court further found that

"not granting the State's motion to consolidate will prejudice the State in that multiple, individual trials will require the State to present its witnesses and evidence in staggering repetition. Separate trials for each Defendant could take years to complete, would impose tremendous economic burden on the State, and would constitute an onerous and unnecessary burden on the State's witnesses, as well as third-party witnesses who would he forced to testify repeatedly. Additionally, the Court finds that multiple trials greatly increase the risk of inconsistent rulings on common issues regarding common questions of law and fact."

The trial court's stated reasons supporting consolidation are similar to and expand upon the reasons the trial court identified in Novartis II as supporting consolidation.

In Novartis II, the trial court's consolidation order stated:

"`The Court further finds that consolidation of these actions promotes effective case management and avoids needlessly duplicative trials. Consolidation of these actions will conserve judicial resources, alleviate unnecessary delay and expense, reduce the burden on witnesses and the parties, and result in the most efficient and economical disposition of these actions. Moreover, the Court finds that the parties will not suffer prejudice as a result of consolidation of the trials of the Consolidated Defendants as these defendants are members of the "Track 1" grouping of cases for trial, originally set for trial in November 2007, and for which the discovery deadline has expired. Finally, the logical grouping of the Consolidated Defendants — all of which manufacture, market and sell brand-name drugs and similarly report prices — minimizes the risk of any prejudice or confusion which could potentially result from consolidation.'"

991 So.2d at 1278.

Moreover, in Novartis II the pharmaceutical companies' contentions were similar to those outlined above; in that case, the pharmaceutical companies argued:

"[T]he trial court exceeded its discretion in ordering a joint trial because `a joint trial of claims against [two] individual manufacturers, each of which, over a 15 year period, sold hundreds of different products that were priced, marketed, and reimbursed in different ways will numb jurors to key distinctions among the defendants, their products, and their marketing practices.' Novartis's petition at 18. Specifically, the pharmaceutical manufacturers argue that their cases involve hundreds of drugs and that the State's claims necessitate demonstrating proof regarding intent, falsity, and reliance as to each defendant that will create an inordinately complex evidentiary record. They further argue that `paralyzed by confusion, jurors will, by default, treat all of the disparate evidence as if it were relevant to all of the defendants. The inevitable prejudice will be substantial.' Novartis's petition at 18.
"In support of their argument, the pharmaceutical manufacturers point to statements made by Judge Patti B. Sardis, the Boston-based federal district judge handling the multidistrict aspects of the AWP litigation. The pharmaceutical manufacturers note that Judge Sardis's experience `led her to conclude that the evidentiary records in [AWP litigation] are simply too complex and confusing for multi-defendant jury trials.' Novartis's petition at 14. Similarly, the pharmaceutical manufacturers point to statements of Circuit Court Judge Richard G. Niess of Dance County, Wisconsin, who noted:
"`[I]t is not at all apparent . . . that any defendant could have its case fairly considered by the jury if not in a separate trial. Defendants present a compelling argument for insurmountable jury confusion with their proof on differing corporate practices among the defendants, multiple claims against each defendant each consisting of multiple elements and each portending multiple verdict questions both on these claims and defendants' affirmative defenses.'
"Novartis's petition at 17. Finally, the pharmaceutical manufacturers note that ` "[t]he very purpose of consolidation is to expedite litigation and save money."` Novartis's petition at 26 (quoting Teague v. Motes, 57 Ala.App. 609, 613, 330 So.2d 434, 439 (Ala.Civ.App. 1976)). However, they argue that a consolidated trial does not promote judicial economy because, the pharmaceutical manufacturers say, consolidation will require the trial court and the defense attorneys to spend an inordinate amount of time keeping separate the claims and evidence attributable to the respective defendants and claims. Novartis's petition at 27. The pharmaceutical manufacturers further argue that `separate trials also minimize the threat of long-term inefficiencies in the form of appellate reversals and retrials.' Novartis's petition at 28."

991 So.2d at 1278-80.

We held that these contentions did not demonstrate that the pharmaceutical companies were entitled to the writ of mandamus. We stated:

"In Quintel Corp., N.V. v. Citibank, N.A., 100 F.R.D. 695, 697 (D.C.N.Y. 1983), the federal district court in New York recognized:

"`This type of danger [jury confusion] exists, of course, in many multidefendant, multicount trials. It is a tenet of the jury system that jurors follow the court's instructions and can apply different standards to several defendants. There is nothing extraordinary about these cases, such as inevitably conflicting findings, that would make the danger of confusion paramount.'
"As the Eleventh Circuit Court of Appeals noted in Hendrix [v. Raybestos-Manhattan, Inc., 776 F.2d 1492 (11th Cir. 1985)], the Court must keep in mind `the extent to which the risks of prejudice and confusion that might attend a consolidated trial can be alleviated by utilizing cautionary instructions to the jury during the trial and controlling the manner in which the plaintiffs' claims (including the defenses thereto) are submitted to the jury for deliberation.' Hendrix, 776 F.2d at 1495.
"Although this Court recognizes that the facts and evidentiary record in these cases may be complex, we cannot conclude that the trial court exceeded its discretion when it consolidated these cases for trial. With the trial of AstraZeneca already having concluded, the remaining consolidated action has only two defendants, Novartis and GSK, and the State has asserted only four claims against each defendant. Under these circumstances, we agree with the State that any prejudice and/or confusion can be avoided or minimized by careful trial management."

991 So.2d at 1279-80.

The primary difference between the present petitions and the petitions in Novartis II is that, as discussed above, Par contends that it did not routinely report pricing information to third-party publishers. However, Par concedes that there were at least isolated instances in which its employees provided that information or confirmed its existence. See supra note 5. At this juncture in the proceedings below, we see no reason why the trial court through careful management will not be able to avoid or minimize any prejudice or confusion that might result from the alleged differences in Par's and Mylan's reporting policies and practices.

As noted above, the trial court cited, in support of consolidation, its experience in managing the previous trials related to this litigation. Par and Mylan attempt to discredit the trial court's experience, however, with arguments like the following:

"Previous [average wholesale price] trials have demonstrated that the cases are too complex for case-management tools to mitigate adequately these prospects of jury confusion and prejudice. . . . In [the GSK/Novartis joint trial] and in the separate AstraZeneca trial, however, the two juries both returned verdicts for the State that this Court later held erroneous as a matter of law. . . . Thus, two separate juries failed to weigh the evidence properly."

(Par's petition, pp. 28-29.) This argument, however, misapprehends what the AstraZeneca decision held. AstraZeneca did not hold, as the petitioners suggest, that the juries "failed to weigh the evidence properly." Rather, AstraZeneca held that "the State failed to produce substantial evidence that it reasonably relied on the misrepresentations and/or fraudulent suppression it alleged AstraZeneca, GSK, and Novartis engaged in in these cases." 41 So.3d at 33. Thus, this Court held that the trial court in AstraZeneca should have granted the defendants' motions for a judgment as a matter of law and that the cases should not have been submitted to the jury for consideration. Id.

Finally, Par asserts that in January 2001 Mylan settled a lawsuit brought against it relating to its version of the drug lorazepam. Par contends that "if evidence about the settlement were admitted at a consolidated trial involving Par, it would create a substantial risk of `guilt by association,' and work to Par's prejudice." (Par's petition, p. 28.) However, Par concedes that the trial court has not yet even addressed the admissibility of that alleged settlement. Consequently, Par's argument that it will be prejudiced by evidence of the alleged settlement is speculative at best.

III.

Both Par and Mylan suggest that this Court should stay the proceedings against them in the trial court pending this Court's resolution of the appeal that has been filed in this Court in Sandoz, Inc. v. State (No. 1081402). Sandoz, Inc., is one of the defendants named in the State's second amended complaint. Par and Mylan contend "[a]ny even arguable questions about the applicability of [the evidence in AstraZeneca regarding Alabama Medicaid's knowledge of drug pricing] to [Alabama Medicaid's] knowledge of generic drug pricing will be resolved when this Court rules on the pending appeal in" Sandoz. The State contends that this aspect of the trial court's ruling — i.e., the denial of Mylan's motion to stay the proceedings pending resolution of the appeal in Sandoz — is not reviewable on a petition for the writ of mandamus. For the reasons expressed in Part I of this opinion, we agree with the State that under these circumstances this issue is not appropriate for review on a petition for the writ of mandamus. The stay of the trial court proceedings that this Court ordered on May 25, 2010, is hereby lifted.

Nothing before us indicates that Par has requested the trial court to stay the proceedings pending resolution of Sandoz.

Conclusion

The petitions for the writ of mandamus are denied.

1090992 — PETITION DENIED; STAY LIFTED.

1090994 — PETITION DENIED; STAY LIFTED.

COBB, C.J., and LYONS, WOODALL, STUART, BOLIN, PARKER, and SHAW, JJ., concur.

MURDOCK, J., dissents.

MURDOCK, Justice (dissenting).

I respectfully dissent for the same reasons I dissented in Ex parte Novartis Pharmaceuticals Corp., 991 So.2d 1263 (Ala. 2008), upon which the main opinion relies. That is, "because of the factual complexity of the claims and defenses of the parties and the likelihood of substantial confusion on the part of the jury and of prejudice to the defendants as a result of the consolidation, I respectfully dissent." Novartis, 991 So.2d at 1280 (Murdock, J., concurring in case no. 1070312 and dissenting in cases no. 1070310 and no. 1070311).

Use AI to get other relevant cases.

Comments

IN RE PAR PHARMACEUTICAL, INC
(Sep 30, 2010)